Verve Therapeutics Alternatives & Competitors

7 companies similar to Verve Therapeutics — Wholly owned subsidiary of Eli Lilly and Company

GENinCode Predictive Genetics

Clinical Genetics and Precision Medicine. Safeguarding your future health.

47 Post-IPO Equity $7.90M

Oxford, United Kingdom

Biotechnology Health Care +1

Compare

Renovacor

Advancing transformative therapies for cardiovascular disease

6 Post-IPO Equity $41.00M

Biotechnology Health Care +1

Compare

Tessera Therapeutics

Pioneering the future of genetic medicine with the power to rewrite the genome and cure di...

21 $682.70M

Biopharma Biotechnology +2

Acrigen Biosciences

Developing life-saving genetic therapies using our proprietary precision gene editing tech...

6 Seed $1.23M

Alameda, United States

Biotechnology Life Sciences

Track all Verve Therapeutics competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Aera Therapeutics

Enabling the next generation of transformative genetic medicines

88 Series B $58.00M

Cambridge, United States

Biotechnology Pharmaceutical

Lexeo Therapeutics

Advancing science with curative potential for both cardiovascular and APOE4 associated Alz...

97 Post-IPO Equity $280.00M

New York, United States

Biotechnology Health and Wellness +1

Ensoma

The future of medicine lies within us.

51 $258.00M

Boston, United States

Biotechnology Health and Wellness +1

About Verve Therapeutics

Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is pioneering a new class of genetic medicines aimed at revolutionizing the treatment of cardiovascular diseases. The company, founded in 2018 and headquartered in the United States, is operating within the Biotechnology, Life Sciences, and Pharmac...

Services

Development of gene editing medicines, Inactivation of liver genes contributing to CVD risk, Advancement of clinical trial pipeline

Target Customers

Patients with cardiovascular disease, Individuals with heterozygous familial hypercholesterolemia, Medical professionals

Business keywords

Genetic Medicine, Cardiovascular Disease, Gene Editing, Lipoprotein Drivers, PCSK9 Gene, ANGPTL3 Gene, LPA Gene, Atherosclerosis Treatment, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Lipoprotein(a) Reduction, Refractory Hypercholesterolemia, Single-course Therapies, ASCVD Treatment

Business Model

B2B, B2B2C

Revenue Model

Product Sales, One Time Purchase, Value Based Pricing

Frequently Asked Questions

Companies similar to Verve Therapeutics include GENinCode Predictive Genetics , Renovacor, Tessera Therapeutics, Acrigen Biosciences, Aera Therapeutics. They work in Biotechnology and Life Sciences and share Verve Therapeutics's focus on cardiovascular disease, genetic medicine and gene editing.

Bounce Watch lists 7 companies that share Verve Therapeutics's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Verve Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Verve Therapeutics Profile GENinCode Predictive Genetics Alternatives Renovacor Alternatives Tessera Therapeutics Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Verve Therapeutics on 15 Jun 2026. The 7 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.